Molecular functions of NEDD4 E3 ubiquitin ligases in cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1856, Issue 1, 2015, Pages 91-106

  Zou, Xiao ^a   Levy Cohen, Gal ^a   Blank, Michael ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

Carcinogenesis; Metastases; NEDD4 E3 ubiquitin ligases; Protein ubiquitination; Ubiquitin

Indexed keywords

ATROPHIN 1 INTERACTING PROTEIN 4; NEDD4 LIKE UBIQUITIN PROTEIN LIGASE 1; NEDD4 LIKE UBIQUITIN PROTEIN LIGASE2 PROTEIN; SMAD UBIQUITIN REGULATORY FACTOR1 PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE NEDD4; UBIQUITIN PROTEIN LIGASE NEDD4L; UNCLASSIFIED DRUG; WWP1 PROTEIN; WWP2 PROTEIN; ESCRT PROTEIN; NEDD4 UBIQUITIN PROTEIN LIGASES; UBIQUITIN PROTEIN LIGASE;

CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; ENZYME ACTIVITY; ENZYME STRUCTURE; HUMAN; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR PROMOTION; UBIQUITINATION; DISEASE COURSE; ENZYMOLOGY; METABOLISM; PATHOLOGY;

DISEASE PROGRESSION; ENDOSOMAL SORTING COMPLEXES REQUIRED FOR TRANSPORT; HUMANS; NEOPLASMS; UBIQUITIN-PROTEIN LIGASES;

EID: 84932599864     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2015.06.005     Document Type: Review

References (176)

1. Popovic D., Vucic D., Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 2014, 20:1242-1253.
2. Jackson S.P., Durocher D. Regulation of DNA damage responses by ubiquitin and SUMO. Mol. Cell 2013, 49:795-807.
3. Thompson L.L., Guppy B.J., Sawchuk L., Davie J.R., McManus K.J. Regulation of chromatin structure via histone post-translational modification and the link to carcinogenesis. Cancer Metastasis Rev. 2013, 32:363-376.
4. Craney A., Rape M. Dynamic regulation of ubiquitin-dependent cell cycle control. Curr. Opin. Cell Biol. 2013, 25:704-710.
5. Fernald K., Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013, 23:620-633.
6. Hershko A., Ciechanover A. The ubiquitin system. Annu. Rev. Biochem. 1998, 67:425-479.
7. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994, 79:13-21.
8. Li W., Bengtson M.H., Ulbrich A., Matsuda A., Reddy V.A., Orth A., et al. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS ONE 2008, 3:e1487.
9. Pierce N.W., Kleiger G., Shan S., Deshaies R.J. Detection of sequential polyubiquitylation on a millisecond timescale. Nature 2009, 462:615-619.
10. Li W., Tu D., Brunger A.T., Ye Y. A ubiquitin ligase transfers preformed polyubiquitin chains from a conjugating enzyme to a substrate. Nature 2007, 446:333-337.
11. Hicke L., Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 2003, 19:141-172.
12. Huang T.T., D'Andrea A.D. Regulation of DNA repair by ubiquitylation. Nat. Rev. Mol. Cell Biol. 2006, 7:323-334.
13. Metzger M.B., Hristova V.A., Weissman A.M. HECT and RING finger families of E3 ubiquitin ligases at a glance. J. Cell Sci. 2012, 125:531-537.
14. Huang L., Kinnucan E., Wang G., Beaudenon S., Howley P.M., Huibregtse J.M., et al. Structure of an E6AP-UbcH7 complex: insights into ubiquitination by the E2-E3 enzyme cascade. Science 1999, 286:1321-1326.
15. Verdecia M.A., Joazeiro C.A.P., Wells N.J., Ferrer J.-L., Bowman M.E., Hunter T., et al. Conformational flexibility underlies ubiquitin ligation mediated by the WWP1 HECT domain E3 ligase. Mol. Cell 2003, 11:249-259.
16. Maspero E., Mari S., Valentini E., Musacchio A., Fish A., Pasqualato S., et al. Structure of the HECT:ubiquitin complex and its role in ubiquitin chain elongation. EMBO Rep. 2011, 12:342-349.
17. Bernassola F., Karin M., Ciechanover A., Melino G. The HECT family of E3 ubiquitin ligases: multiple players in cancer development. Cancer Cell 2008, 14:10-21.
18. Lee J.R.E., Oestreich A.J., Payne J.A., Gunawan M.S., Norgan A.P., Katzmann D.J. The HECT domain of the ubiquitin ligase Rsp5 contributes to substrate recognition. J. Biol. Chem. 2009, 284:32126-32137.
19. Wang X., Shi Y., Wang J., Huang G., Jiang X. Crucial role of the C-terminus of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation. Biochem. J. 2008, 414:221-229.
20. Zhou W., Xu J., Zhao Y., Sun Y. SAG/RBX2 is a novel substrate of NEDD4-1 E3 ubiquitin ligase and mediates NEDD4-1 induced chemosensitization. Oncotarget 2014, 5:6746-6755.
21. Chen C., Matesic L. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 2007, 26:587-604.
22. 2+-binding domain. J. Biol. Chem. 1998, 273:15879-15882.
23. 2+-dependent plasma membrane localization. J. Biol. Chem. 1997, 272:32329-32336.
24. Ingham R.J., Colwill K., Howard C., Dettwiler S., Lim C.S.H., Yu J., et al. WW domains provide a platform for the assembly of multiprotein networks. Mol. Cell. Biol. 2005, 25:7092-7106.
25. Dodson E.J., Fishbain-Yoskovitz V., Rotem-Bamberger S., Schueler-Furman O. Versatile communication strategies among tandem WW domain repeats. Exp. Biol. Med. (Maywood) 2015, 240:351-360.
26. Kanelis V., Bruce M.C., Skrynnikov N.R., Rotin D., Forman-Kay J.D. Structural determinants for high-affinity binding in a Nedd4 WW3* domain-Comm PY motif complex. Structure 2006, 14:543-553.
27. An H., Krist D.T., Statsyuk A.V. Crosstalk between kinases and Nedd4 family ubiquitin ligases. Mol. BioSyst. 2014, 10:1643-1657.
28. Shearwin-Whyatt L., Dalton H.E., Foot N., Kumar S. Regulation of functional diversity within the Nedd4 family by accessory and adaptor proteins. Bioessays 2006, 28:617-628.
29. Yang B., Kumar S. Nedd4 and Nedd4-2: closely related ubiquitin-protein ligases with distinct physiological functions. Cell Death Differ. 2010, 17:68-77.
30. Kumar S., Tomooka Y., Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem. Biophys. Res. Commun. 1992, 185:1155-1161.
31. + channel deleted in Liddle's syndrome. EMBO J. 1996, 15:2371-2380.
32. + channel (ENaC) by ubiquitination. EMBO J. 1997, 16:6325-6336.
33. +. J. Biol. Chem. 1999, 274:12525-12530.
34. Cao X.R., Lill N.L., Boase N., Shi P.P., Croucher D.R., Shan H., et al. Nedd4 controls animal growth by regulating IGF-1 signaling. Sci. Signal. 2008, 1:ra5.
35. Sun A., Yu G., Dou X., Yan X., Yang W., Lin Q. Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis. Mol. Cancer 2014, 13:248.
36. Hong S.-W., Moon J.-H., Kim J.-S., Shin J.-S., Jung K.-A., Lee W.-K., et al. p34 is a novel regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death Differ. 2014, 21:146-160.
37. Jung S., Li C., Jeong D., Lee S., Ohk J., Park M., et al. Oncogenic function of p34SEI-1 via NEDD4-1-mediated PTEN ubiquitination/degradation and activation of the PI3K/AKT pathway. Int. J. Oncol. 2013, 43:1587-1595.
38. Amodio N., Scrima M., Palaia L., Salman A.N., Quintiero A., Franco R., et al. Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am. J. Pathol. 2010, 177:2622-2634.
39. Wang X., Trotman L.C., Koppie T., Alimonti A., Chen Z., Gao Z., et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 2007, 128:129-139.
40. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
41. Fouladkou F., Landry T., Kawabe H., Neeb A., Lu C., Brose N., et al. The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8585-8590.
42. Yim E.-K., Peng G., Dai H., Hu R., Li K., Lu Y., et al. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15:304-314.
43. Zeng T., Wang Q., Fu J., Lin Q., Bi J., Ding W., et al. Impeded Nedd4-1-mediated Ras degradation underlies Ras-driven tumorigenesis. Cell Rep. 2014, 7:871-882.
44. Trotman L.C., Wang X., Alimonti A., Chen Z., Teruya-Feldstein J., Yang H., et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007, 128:141-156.
45. Shen W.H., Balajee A.S., Wang J., Wu H., Eng C., Pandolfi P.P., et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007, 128:157-170.
46. Choi B.H., Chen Y., Dai W. Chromatin PTEN is involved in DNA damage response partly through regulating Rad52 sumoylation. Cell Cycle 2013, 12:3442-3447.
47. Bassi C., Ho J., Srikumar T., Dowling R.J.O., Gorrini C., Miller S.J., et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013, 341:395-399.
48. Mund T., Pelham H.R.B. Control of the activity of WW-HECT domain E3 ubiquitin ligases by NDFIP proteins. EMBO Rep. 2009, 10:501-507.
49. Helliwell S.B., Losko S., Kaiser C.A. Components of a ubiquitin ligase complex specify polyubiquitination and intracellular trafficking of the general amino acid permease. J. Cell Biol. 2001, 153:649-662.
50. Dai B., Pieper R.O., Li D., Wei P., Liu M., Woo S.Y., et al. FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. Cancer Res. 2010, 70:2951-2961.
51. Shadfan M., Lopez-Pajares V., Yuan Z.-M. MDM2 and MDMX: alone and together in regulation of p53. Transl. Cancer Res. 2012, 1:88-99.
52. Bieging K.T., Mello S.S., Attardi L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer 2014, 14:359-370.
53. Xu C., Fan C.D., Wang X. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase. Oncogene 2015, 34:281-289.
54. Vecchione A., Marchese A., Henry P., Rotin D., Morrione A. The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol. Cell. Biol. 2003, 23:3363-3372.
55. Magnifico A., Ettenberg S., Yang C., Mariano J., Tiwari S., Fang S., et al. WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J. Biol. Chem. 2003, 278:43169-43177.
56. Marmor M.D., Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 2004, 23:2057-2070.
57. Liu P.Y., Xu N., Malyukova A., Scarlett C.J., Sun Y.T., Zhang X.D., et al. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ. 2013, 20:503-514.
58. Boase N.A., Rychkov G.Y., Townley S.L., Dinudom A., Candi E., Voss A.K., et al. Respiratory distress and perinatal lethality in Nedd4-2-deficient mice. Nat. Commun. 2011, 2:287.
59. Kuratomi G., Komuro A., Goto K., Shinozaki M., Miyazawa K., Miyazono K., et al. NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF-b (transforming growth factor-b) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF-b type I receptor. Biochem. J. 2005, 386:461-470.
60. Gao S., Alarcón C., Sapkota G., Rahman S., Chen P.-Y., Goerner N., et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-β signaling. Mol. Cell 2009, 36:457-468.
61. Ding Y., Zhang Y., Xu C., Tao Q.-H., Chen Y.-G. HECT domain-containing E3 ubiquitin ligase NEDD4L negatively regulates Wnt signaling by targeting dishevelled for proteasomal degradation. J. Biol. Chem. 2013, 288:8289-8298.
62. Tanksley J.P., Chen X., Coffey R.J. NEDD4L is downregulated in colorectal cancer and inhibits canonical WNT signaling. PLoS ONE 2013, 8:e81514.
63. Chan W., Tian R., Lee Y.-F., Sit S.T., Lim L., Manser E. Down-regulation of active ACK1 is mediated by association with the E3 ubiquitin ligase Nedd4-2. J. Biol. Chem. 2009, 284:8185-8194.
64. Lebrun J.-J. The dual role of TGFβ in human cancer: from tumor suppression to cancer metastasis. ISRN Mol. Biol. 2012, 2012:1-28.
65. Hellwinkel O.J.C., Asong L.E., Rogmann J.P., Sultmann H., Wagner C., Schlomm T., et al. Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma. Prostate Cancer Prostatic Dis. 2011, 14:38-45.
66. Takeuchi T., Adachi Y., Nagayama T., Furihata M. Nedd4L modulates the transcription of metalloproteinase-1 and -13 genes to increase the invasive activity of gallbladder cancer. Int. J. Exp. Pathol. 2011, 92:79-86.
67. Johansson N., Ala-aho R., Uitto V., Grenman R., Fusenig N.E., Lopez-Otin C., et al. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J. Cell Sci. 2000, 113:227-235.
68. Kito Y., Bai J., Goto N., Okubo H., Adachi Y., Nagayama T., et al. Pathobiological properties of the ubiquitin ligase Nedd4L in melanoma. Int. J. Exp. Pathol. 2014, 95:24-28.
69. Sakashita H., Inoue H., Akamine S., Ishida T., Inase N., Shirao K., et al. Identification of the NEDD4L gene as a prognostic marker by integrated microarray analysis of copy number and gene expression profiling in non-small cell lung cancer. Ann. Surg. Oncol. 2013, 20(Suppl. 3):S590-S598.
70. Gao C., Pang L., Ren C., Ma T. Decreased expression of Nedd4L correlates with poor prognosis in gastric cancer patient. Med. Oncol. 2012, 29:1733-1738.
71. He S., Deng J., Li G., Wang B., Cao Y., Tu Y. Down-regulation of Nedd4L is associated with the aggressive progression and worse prognosis of malignant glioma. Jpn. J. Clin. Oncol. 2012, 42:196-201.
72. González-Sancho J.M., Greer Y.E., Abrahams C.L., Takigawa Y., Baljinnyam B., Lee K.H., et al. Functional consequences of Wnt-induced dishevelled 2 phosphorylation in canonical and noncanonical Wnt signaling. J. Biol. Chem. 2013, 288:9428-9437.
73. Polakis P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 2012, 4:a008052.
74. Lee H.-S., Park M.-H., Yang S.-J., Park K.C., Kim N.-S., Kim Y.-S., et al. Novel candidate targets of Wnt/β-catenin signaling in hepatoma cells. Life Sci. 2007, 80:690-698.
75. 18H mice. Nat. Genet. 1998, 18:143-146.
76. Fang D., Elly C., Gao B., Fang N., Altman Y., Joazeiro C., et al. Dysregulation of T lymphocyte function in itchy mice: a role for Itch in TH2 differentiation. Nat. Immunol. 2002, 3:281-287.
77. Melino G., Gallagher E., Aqeilan R.I., Knight R., Peschiaroli A., Rossi M., et al. Itch: a HECT-type E3 ligase regulating immunity, skin and cancer. Cell Death Differ. 2008, 15:1103-1112.
78. Lohr N.J., Molleston J.P., Strauss K.A., Torres-Martinez W., Sherman E.A., Squires R.H., et al. Human ITCH E3 ubiquitin ligase deficiency causes syndromic multisystem autoimmune disease. Am. J. Hum. Genet. 2010, 86:447-453.
79. Ahmed N., Zeng M., Sinha I., Polin L., Wei W.-Z., Rathinam C., et al. The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 2011, 12:1176-1183.
80. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol. Sci. 2012, 33:522-530.
81. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol. 2009, 30:383-391.
82. Ma A., Malynn B.A. A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat. Rev. Immunol. 2012, 12:774-785.
83. Shembade N., Parvatiyar K., Harhaj N.S., Harhaj E.W. The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-κB signalling. EMBO J. 2009, 28:513-522.
84. Fang D., Kerppola T.K. Ubiquitin-mediated fluorescence complementation reveals that Jun ubiquitinated by Itch/AIP4 is localized to lysosomes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:14782-14787.
85. L turnover. Cell 2006, 124:601-613.
86. Abu-Odeh M., Bar-Mag T., Huang H., Kim T., Salah Z., Abdeen S.K., et al. Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks. J. Biol. Chem. 2014, 289:8865-8880.
87. Rossi M., De Laurenzi V., Munarriz E., Green D.R., Liu Y.-C., Vousden K.H., et al. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 2005, 24:836-848.
88. Rossi M., Aqeilan R.I., Neale M., Candi E., Salomoni P., Knight R.A., et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:12753-12758.
89. Suryaraja R., Anitha M., Anbarasu K., Kumari G., Mahalingam S. The E3 ubiquitin ligase Itch regulates tumor suppressor protein RASSF5/NORE1 stability in an acetylation-dependent manner. Cell Death Dis. 2013, 4:e565.
90. Salah Z., Melino G., Aqeilan R.I. Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 2011, 71:2010-2020.
91. Ho K.C., Zhou Z., She Y.-M., Chun A., Cyr T.D., Yang X. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4870-4875.
92. Chen X.L., Chinchilla P., Fombonne J., Ho L., Guix C., Keen J.H., et al. Patched-1 proapoptotic activity is downregulated by modification of K1413 by the E3 ubiquitin-protein ligase Itchy homolog. Mol. Cell. Biol. 2014, 34:3855-3866.
93. Moll U.M., Slade N. p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2004, 2:371-386.
94. Flores E.R., Sengupta S., Miller J.B., Newman J.J., Bronson R., Crowley D., et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005, 7:363-373.
95. Hansen T.M., Rossi M., Roperch J.P., Ansell K., Simpson K., Taylor D., et al. Itch inhibition regulates chemosensitivity in vitro. Biochem. Biophys. Res. Commun. 2007, 361:33-36.
96. Overmeyer J.H., Maltese W.A. Death pathways triggered by activated Ras in cancer cells. Front. Biosci. 2011, 16:1693-1713.
97. Harvey K.F., Zhang X., Thomas D.M. The Hippo pathway and human cancer. Nat. Rev. Cancer 2013, 13:246-257.
98. Moroishi T., Hansen C.G., Guan K.-L. The emerging roles of YAP and TAZ in cancer. Nat. Rev. Cancer 2015, 15:73-79.
99. Salah Z., Itzhaki E., Aqeilan R.I. The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway. Oncotarget 2014, 5:10886-10900.
100. Xie J., Bartels C.M., Barton S.W., Gu D. Targeting hedgehog signaling in cancer: research and clinical developments. Oncol. Targets Ther. 2013, 6:1425-1435.
101. Mille F., Thibert C., Fombonne J., Rama N., Guix C., Hayashi H., et al. The patched dependence receptor triggers apoptosis through a DRAL-caspase-9 complex. Nat. Cell Biol. 2009, 11:739-746.
102. Di Marcotullio L., Ferretti E., Greco A., De Smaele E., Po A., Sico M.A., et al. Numb is a suppressor of hedgehog signalling and targets Gli1 for Itch-dependent ubiquitination. Nat. Cell Biol. 2006, 8:1415-1423.
103. Di Marcotullio L., Greco A., Mazzà D., Canettieri G., Pietrosanti L., Infante P., et al. Numb activates the E3 ligase Itch to control Gli1 function through a novel degradation signal. Oncogene 2011, 30:65-76.
104. Levy D., Adamovich Y., Reuven N., Shaul Y. The yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death Differ. 2007, 14:743-751.
105. Oberst A., Malatesta M., Aqeilan R.I., Rossi M., Salomoni P., Murillas R., et al. The Nedd4-binding partner 1 (N4BP1) protein is an inhibitor of the E3 ligase Itch. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:11280-11285.
106. Gallagher E., Gao M., Liu Y.-C., Karin M. Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1717-1722.
107. Santini S., Stagni V., Giambruno R., Fianco G., Di Benedetto A., Mottolese M., et al. ATM kinase activity modulates ITCH E3-ubiquitin ligase activity. Oncogene 2014, 33:1113-1123.
108. Wood J.D., Yuan J., Margolis R.L., Colomer V., Duan K., Kushi J., et al. Atrophin-1, the DRPLA gene product, interacts with two families of WW domain-containing proteins. Mol. Cell. Neurosci. 1998, 11:149-160.
109. Zhi X., Chen C. WWP1: a versatile ubiquitin E3 ligase in signaling and diseases. Cell. Mol. Life Sci. 2012, 69:1425-1434.
110. Chen C., Zhou Z., Ross J.S., Zhou W., Dong J.-T. The amplified WWP1 gene is a potential molecular target in breast cancer. Int. J. Cancer 2007, 121:80-87.
111. Chen C., Zhou Z., Sheehan C.E., Slodkowska E., Sheehan C.B., Boguniewicz A., et al. Overexpression of WWP1 is associated with the estrogen receptor and insulin-like growth factor receptor 1 in breast carcinoma. Int. J. Cancer 2009, 124:2829-2836.
112. Chen C., Sun X., Guo P., Dong X.Y., Sethi P., Zhou W., et al. Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer. Oncogene 2006, 26:2386-2394.
113. Lin J.-H., Hsieh S.-C., Chen J.-N., Tsai M.-H., Chang C.-C. WWP1 gene is a potential molecular target of human oral cancer. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2013, 116:221-231.
114. Cheng Q., Cao X., Yuan F., Li G., Tong T. Knockdown of WWP1 inhibits growth and induces apoptosis in hepatoma carcinoma cells through the activation of caspase3 and p53. Biochem. Biophys. Res. Commun. 2014, 448:248-254.
115. Zhang L., Wu Z., Ma Z., Liu H., Wu Y., Zhang Q. WWP1 as a potential tumor oncogene regulates PTEN-Akt signaling pathway in human gastric carcinoma. Tumor Biol. 2015, 36:787-798.
116. Laine A., Ronai Z. Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1. Oncogene 2006, 26:1477-1483.
117. Li M., Brooks C.L., Wu-Baer F., Chen D., Baer R., Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003, 302:1972-1975. (80-.).
118. Li Y., Zhou Z., Chen C. WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ. 2008, 15:1941-1951.
119. Peschiaroli A., Scialpi F., Bernassola F., El Sherbini E.S., Melino G. The E3 ubiquitin ligase WWP1 regulates δNp63-dependent transcription through Lys63 linkages. Biochem. Biophys. Res. Commun. 2014, 402:425-430.
120. Li C., Chang D.L., Yang Z., Qi J., Liu R., He H., et al. Pin1 modulates p63α protein stability in regulation of cell survival, proliferation and tumor formation. Cell Death Dis 2013, 4:e943.
121. Chaudhary N., Maddika S. WWP2-WWP1 ubiquitin ligase complex coordinated by PPM1G maintains the balance between cellular p73 and δNp73 levels. Mol. Cell. Biol. 2014, 34:3754-3764.
122. Zhang X., Srinivasan S.V., Lingrel J.B. WWP1-dependent ubiquitination and degradation of the lung Krüppel-like factor, KLF2. Biochem. Biophys. Res. Commun. 2004, 316:139-148.
123. Chen C., Sun X., Guo P., Dong X.-Y., Sethi P., Cheng X., et al. Human Kruppel-like factor 5 is a target of the E3 ubiquitin ligase WWP1 for proteolysis in epithelial cells. J. Biol. Chem. 2005, 280:41553-41561.
124. McConnell B.B., Yang V.W. Mammalian Krüppel-like factors in health and diseases. Physiol. Rev. 2010, 90:1337-1381.
125. Zhi X., Zhao D., Zhou Z., Liu R., Chen C. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor. Am. J. Pathol. 2012, 180:2452-2461.
126. Zhao D., Zhi X., Zhou Z., Chen C. TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis 2012, 33:59-67.
127. Strano S., Munarriz E., Rossi M., Castagnoli L., Shaul Y., Sacchi A., et al. Physical interaction with yes-associated protein enhances p73 transcriptional activity. J. Biol. Chem. 2001, 276:15164-15173.
128. Yeung B., Ho K.-C., Yang X. WWP1 E3 ligase targets LATS1 for ubiquitin-mediated degradation in breast cancer cells. PLoS ONE 2013, 8:e61027.
129. Chen C., Zhou Z., Liu R., Li Y., Azmi P.B., Seth A.K. The WW domain containing E3 ubiquitin protein ligase 1 upregulates ErbB2 and EGFR through RING finger protein 11. Oncogene 2008, 27:6845-6855.
130. Arteaga C.L., Engelman J.A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeuticsa. Cancer Cell 2014, 25:282-303.
131. Azmi P., Seth A. RNF11 is a multifunctional modulator of growth factor receptor signalling and transcriptional regulation. Eur. J. Cancer 2005, 41:2549-2560.
132. Kitching R., Wong M.J., Koehler D., Burger A.M., Landberg G., Gish G., et al. The RING-H2 protein RNF11 is differentially expressed in breast tumours and interacts with HECT-type E3 ligases. Biochim. Biophys. Acta 2003, 1639:104-112.
133. Subramaniam V., Li H., Wong M., Kitching R., Attisano L., Wrana J., et al. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br. J. Cancer 2003, 89:1538-1544.
134. Feng S.-M., Muraoka-Cook R.S., Hunter D., Sandahl M.A., Caskey L.S., Miyazawa K., et al. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol. Cell. Biol. 2009, 29:892-906.
135. Li Y., Zhou Z., Alimandi M., Chen C. WW domain containing E3 ubiquitin protein ligase 1 targets the full-length ErbB4 for ubiquitin-mediated degradation in breast cancer. Oncogene 2009, 28:2948-2958.
136. Komuro A., Nagai M., Navin N.E., Sudol M. WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J. Biol. Chem. 2003, 278:33334-33341.
137. Shu L., Zhang H., Boyce B.F., Xing L. Ubiquitin E3 ligase Wwp1 negatively regulates osteoblast function by inhibiting osteoblast differentiation and migration. J. Bone Miner. Res. 2013, 28:1925-1935.
138. Subik K., Shu L., Wu C., Liang Q., Hicks D., Boyce B., et al. The ubiquitin E3 ligase WWP1 decreases CXCL12-mediated MDA231 breast cancer cell migration and bone metastasis. Bone 2012, 50:813-823.
139. Komuro A., Imamura T., Saitoh M., Yoshida Y., Yamori T., Miyazono K., et al. Negative regulation of transforming growth factor-βTGF-β) signaling by WW domain-containing protein 1 (WWP1). Oncogene 2004, 23:6914-6923.
140. Maddika S., Kavela S., Rani N., Palicharla V.R., Pokorny J.L., Sarkaria J.N., et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 2011, 13:728-733.
141. Fukumoto C., Nakashima D., Kasamatsu A., Unozawa M., Shida-Sakazume T., Higo M., et al. WWP2 is overexpressed in human oral cancer, determining tumor size and poor prognosis in patients: downregulation of WWP2 inhibits the AKT signaling and tumor growth in mice. Oncoscience 2014, 1:807-820.
142. Jung J.-G., Stoeck A., Guan B., Wu R.-C., Zhu H., Blackshaw S., et al. Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. PLoS Genet. 2014, 10:e1004751.
143. Hu W., Liu T., Ivan C., Sun Y., Huang J., Mangala L.S., et al. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014, 74:3282-3293.
144. Miyazaki K., Fujita T., Ozaki T., Kato C., Kurose Y., Sakamoto M., et al. NEDL1, a novel ubiquitin-protein isopeptide ligase for dishevelled-1, targets mutant superoxide dismutase-1. J. Biol. Chem. 2004, 279:11327-11335.
145. Zhang L., Haraguchi S., Koda T., Hashimoto K., Nakagawara A. Muscle atrophy and motor neuron degeneration in human NEDL1 transgenic mice. J. Biomed. Biotechnol. 2011, 2011:831092.
146. Li Y., Ozaki T., Kikuchi H., Yamamoto H., Ohira M., Nakagawara A. A novel HECT-type E3 ubiquitin protein ligase NEDL1 enhances the p53-mediated apoptotic cell death in its catalytic activity-independent manner. Oncogene 2008, 27:3700-3709.
147. Lu L., Hu S., Wei R., Qiu X., Lu K., Fu Y., et al. The HECT type ubiquitin ligase NEDL2 is degraded by anaphase-promoting complex/cyclosome (APC/C)-Cdh1, and its tight regulation maintains the metaphase to anaphase transition. J. Biol. Chem. 2013, 288:35637-35650.
148. Miyazaki K., Ozaki T., Kato C., Hanamoto T., Fujita T., Irino S., et al. A novel HECT-type E3 ubiquitin ligase, NEDL2, stabilizes p73 and enhances its transcriptional activity. Biochem. Biophys. Res. Commun. 2003, 308:106-113.
149. Zhu H., Kavsak P., Abdollah S., Wrana J.L., Thomsen G.H. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999, 400:687-693.
150. Lin X., Liang M., Feng X.-H. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-β signaling. J. Biol. Chem. 2000, 275:36818-36822.
151. Zhang Y., Chang C., Gehling D.J., Hemmati-Brivanlou A., Derynck R. Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase. Proc. Natl. Acad. Sci. 2001, 98:974-979.
152. David D., Nair S.A., Pillai M.R. Smurf E3 ubiquitin ligases at the cross roads of oncogenesis and tumor suppression. Biochim. Biophys. Acta Rev. Cancer 2013, 1835:119-128.
153. Bai Y., Yang C., Hu K., Elly C., Liu Y.-C. Itch E3 ligase-mediated regulation of TGF-β signaling by modulating smad2 phosphorylation. Mol. Cell 2004, 15:825-831.
154. Yamashita M., Ying S.-X., Zhang G., Li C., Cheng S.Y., Deng C., et al. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 2005, 121:101-113.
155. Narimatsu M., Bose R., Pye M., Zhang L., Miller B., Ching P., et al. Regulation of planar cell polarity by Smurf ubiquitin ligases. Cell 2009, 137:295-307.
156. Loukopoulos P., Shibata T., Katoh H., Kokubu A., Sakamoto M., Yamazaki K., et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci. 2007, 98:392-400.
157. Yu L., Liu X., Cui K., Di Y., Xin L., Sun X., et al. SND1 acts downstream of TGFβ1 and upstream of Smurf1 to promote breast cancer metastasis. Cancer Res. 2015, 75:1275-1286.
158. Wang W., Ren F., Wu Q., Jiang D., Li H., Peng Z., et al. MicroRNA-497 inhibition of ovarian cancer cell migration and invasion through targeting of SMAD specific E3 ubiquitin protein ligase 1. Biochem. Biophys. Res. Commun. 2014, 449:432-437.
159. Gang X., Wang G., Huang H. Androgens regulate SMAD ubiquitination regulatory factor-1 expression and prostate cancer cell invasion. Prostate 2015, 75:561-572.
160. Khammanivong A., Gopalakrishnan R., Dickerson E.B. SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma. Mol. Cancer 2014, 13:260.
161. Tang L.-Y., Yamashita M., Coussens N.P., Tang Y., Wang X., Li C., et al. Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3. EMBO J. 2011, 30:4777-4789.
162. Blank M., Tang Y., Yamashita M., Burkett S.S., Cheng S.Y., Zhang Y.E. A tumor suppressor function of Smurf2 associated with controlling chromatin landscape and genome stability through RNF20. Nat. Med. 2012, 18:227-234.
163. Ramkumar C., Kong Y., Cui H., Hao S., Jones S.N., Gerstein R.M., et al. Smurf2 regulates the senescence response and suppresses tumorigenesis in mice. Cancer Res. 2012, 72:2714-2719.
164. Liu X., Gu X., Sun L., Flowers A.B., Rademaker A.W., Zhou Y., et al. Downregulation of Smurf2, a tumor-suppressive ubiquitin ligase, in triple-negative breast cancers: involvement of the RB-microRNA axis. BMC Cancer 2014, 14:57.
165. Minsky N., Shema E., Field Y., Schuster M., Segal E., Oren M. Monoubiquitinated H2B is associated with the transcribed region of highly expressed genes in human cells. Nat. Cell Biol. 2008, 10:483-488.
166. Moyal L., Lerenthal Y., Gana-Weisz M., Mass G., So S., Wang S.-Y., et al. Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. Mol. Cell 2011, 41:529-542.
167. Jin C., Yang Y., Anver M.R., Morris N., Wang X., Zhang Y.E. Smad ubiquitination regulatory factor 2 promotes metastasis of breast cancer cells by enhancing migration and invasiveness. Cancer Res. 2009, 69:735-740.
168. Wang Z., Wang J., Li X., Xing L., Ding Y., Shi P., et al. Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2. Int. J. Oncol. 2014, 45:1469-1478.
169. Fukuchi M., Fukai Y., Masuda N., Miyazaki T., Nakajima M., Sohda M., et al. High-level expression of the Smad ubiquitin ligase Smurf2 correlates with poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Res. 2002, 62:7162-7165.
170. Fukasawa H., Yamamoto T., Fujigaki Y., Misaki T., Ohashi N., Takayama T., et al. Reduction of transforming growth factor-β type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma. Int. J. Cancer 2010, 127:1517-1525.
171. Du J.X., Hagos E.G., Nandan M.O., Bialkowska A.B., Yu B., Yang V.W. The E3 ubiquitin ligase SMAD ubiquitination regulatory factor 2 negatively regulates Krüppel-like factor 5 protein. J. Biol. Chem. 2011, 286:40354-40364.
172. Kong Y., Cui H., Zhang H. Smurf2-mediated ubiquitination and degradation of Id1 regulates p16 expression during senescence. Aging Cell 2011, 10:1038-1046.
173. Osmundson E.C., Ray D., Moore F.E., Gao Q., Thomsen G.H., Kiyokawa H. The HECT E3 ligase Smurf2 is required for Mad2-dependent spindle assembly checkpoint. J. Cell Biol. 2008, 183:267-277.
174. Wu Q., Huang J.H., Sampson E.R., Kim K.-O.K., Zuscik M.J., O'Keefe R.J., et al. Smurf2 induces degradation of GSK-3β and upregulates β-catenin in chondrocytes: a potential mechanism for Smurf2-induced degeneration of articular cartilage. Exp. Cell Res. 2009, 315:2386-2398.
175. Kim S., Jho E. The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2). J. Biol. Chem. 2010, 285:36420-36426.
176. Shukla S., Allam U.S., Ahsan A., Chen G., Krishnamurthy P.M., Marsh K., et al. KRAS protein stability is regulated through SMURF2: UBCH5 complex-mediated β-TrCP1 degradation. Neoplasia 2014, 16:115-128.